drugset
Drugs / Bel-sar
last change Jun 2026 re-read 3 minutes ago

Bel-sar

Developed for
malignant choroid melanoma
Investigated by
Aura Biosciences

Trials 1

today NCT06007690 · Ph 3
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06007690 Dec 2023 → Nov 2027 expected malignant choroid melanoma Aura Biosciences Recruiting No outcome recorded

Press releases naming this drug 9 releases

DateIssuerRelease
2026-06-01 Aura Biosciences Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma aurabiosciences.com ↗
2025-03-24 Aura Biosciences Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress aurabiosciences.com ↗
2024-10-17 Aura Biosciences Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial aurabiosciences.com ↗
2024-09-12 Aura Biosciences Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma aurabiosciences.com ↗
2024-08-26 Aura Biosciences Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting aurabiosciences.com ↗
2023-12-07 Aura Biosciences Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma aurabiosciences.com ↗
2023-11-06 Aura Biosciences Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma aurabiosciences.com ↗
2023-10-31 Aura Biosciences Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 aurabiosciences.com ↗
2023-02-16 Aura Biosciences Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration at the Macula Society 46th Annual Meeting aurabiosciences.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bel-sar ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007690 ↗
Route Other “Bel-sar via suprachoroidal administration followed by laser application.” NCT06007690 ↗